CHAMGAP
APPROVEDReviewed and approved by the Chamgap Editorial Team (2026-07-11). The draft was written by AI, the existence of all 4 cited sources was verified at the original page, and the verdict passed blind grading and adversarial audit. Methodology v0.6.
Verdict No. 279 · Search date 2026-07-11 · Methodology v0.6

D-ribose,
does it really help with Improved fatigue in chronic fatigue syndrome and fibromyalgia?

30-Second Summary
C
Evidence Grade C · 40 · Safety caution
Open-label studies show a fatigue signal, but placebo-controlled confirmation is absent
What the
research shows
CFS and fibromyalgia fatigue has only open-label, uncontrolled self-reported improvement signals, placing it in the lower C range. Mental fatigue was not improved in a placebo-controlled crossover trial of 17 healthy adults, so that subclaim is D.
What the
ads claim
Advertisements describe ATP replenishment and recovery from chronic fatigue as established, while the disease-specific evidence consists of self-reported open-label studies.
*

Useful facts when choosing a product

  • Disease studies generally used 5 g three times daily.
  • Main outcomes were self-reported energy, sleep, cognition, pain, and well-being.
  • Transient blood-glucose reductions may occur at doses of 5 g or more.
Gap Measurement · Verdict 279 · C 40
What advertising claims
What independent, higher-quality research supports
△ GAP
01

What the research actually shows

Teitelbaum 2006 gave 5 g three times daily to 41 patients and reported improvement in energy and other visual-analogue measures. Teitelbaum 2012 reported improvements among 203 completers from 257 patients, but it was also unblinded and uncontrolled and included authors employed by the product company. In Ataka 2008, D-ribose at 2 g/day did not improve mental fatigue in a double-blind, placebo-controlled, three-way crossover trial of 17 healthy adults.

02

Why this is classified as C (40)

The human signal for CFS and fibromyalgia is concentrated in uncontrolled self-report data, while the placebo-controlled healthy-adult fatigue trial was null, resulting in lower-C with 40 points.

Counterpoint. Similar self-reported signals were observed in both chronic fatigue syndrome and fibromyalgia.

Rejudgment record. Reassessment (cross-check reflected) — CFS and fibromyalgia evidence is limited to open-label, uncontrolled self-report, and the 17-person placebo-controlled crossover trial in healthy adults was null

Sub-claim grades by effect

This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.

Effect (sub-claim)GradeBasis
CFS and fibromyalgia fatigueCLower-C signal from open-label, uncontrolled self-report
Fatigue in healthy adultsDNull 17-person crossover trial

Cross-check — Codex and Claude

This verdict was drafted by Codex through literature review and source-existence checks, cross-checked through blind grading and adversarial audit, and settled by reapplying the methodology boundary rules. Cases with split grades were resolved through rejudgment.
03

Evidence Table

StudyDesignSampleFundingEndpointResultWeight
Teitelbaum JE et al. 2006Open-label uncontrolled pilot41Possible product-related interests; details unknownVisual-analogue ratings of energy, sleep, cognition, pain, and well-beingAll visual-analogue categories improved from baseline with 15 g/day.Limited
Teitelbaum J et al. 2012Multicenter open-label uncontrolled trial203Corvalen supplied free; product-company authorsEnergy, sleep, cognition, pain, and well-beingAll self-reported measures improved among completers after three weeks.Limited, industry-linked
Ataka S et al. 2008Double-blind placebo-controlled three-way crossover trial17Details unknownMental fatigue and cognitive-task performanceD-ribose at 2 g/day did not improve mental fatigue versus placebo.Direct, negative
§

Receipt — 4 References

All 4 cited sources were verified for existence at the original page (as of 2026-07-11).

Teitelbaum JE, Johnson C, St Cyr J. The use of D-ribose in chronic fatigue syndrome and fibromyalgia: a pilot study. J Altern Complement Med. 2006;12(9):857-862. PMID: 17109576. DOI: 10.1089/acm.2006.12.857.
checked
Teitelbaum J, Jandrain J, McGrew R. Treatment of chronic fatigue syndrome and fibromyalgia with D-ribose—an open-label, multicenter study. Open Pain J. 2012;5:32-37. DOI: 10.2174/1876386301205010032.
checked
EFSA Panel on Nutrition, Novel Foods and Food Allergens. Safety of D-ribose as a novel food pursuant to Regulation (EU) 2015/2283. EFSA J. 2018;16(5):5265. DOI: 10.2903/j.efsa.2018.5265.
checked
Ataka S, Tanaka M, Nozaki S, et al. Effects of oral administration of caffeine and D-ribose on mental fatigue. Nutrition. 2008;24(3):233-238. PMID: 18178380. DOI: 10.1016/j.nut.2007.12.002.
checked
Draft and rewrite: Codex (AI) · Verification: Codex blind grading and adversarial audit · Final adjudication: Claude
Reviewed and approved: Chamgap Editorial Team · Approval date: 2026-07-11 · Corrections: none

Cite this verdict

D-ribose x improved fatigue in chronic fatigue syndrome and fibromyalgia Evidence Grade C card
[Chamgap] D-ribose x improved fatigue in chronic fatigue syndrome and fibromyalgia — Evidence Grade C·40. 4 cited sources checked. Source: https://health-receipt.pages.dev/en/verdicts/energy/d-ribose-chronic-fatigue-fibromyalgia/ · CC BY 4.0

CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.

!

What this document does and does not do

Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.